Annexin 1 antibody

Abstract

The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG. 2A. The present invention also relates to the sue of such a specific binding molecule in the treatment of T cell-mediated disease.

The invention claimed is: 
     
       1. An antibody or fragment thereof that binds human Anx-A1 having the amino acid sequence of SEQ ID NO:8, said antibody or fragment thereof comprising Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which
   VLCDR1 is KASENVVTYVS  (SEQ ID NO:2)
 
   VLCDR2 is GASNRYT  (SEQ ID NO:3)
 
   VLCDR3 is GQGYSYPYT  (SEQ ID NO:4)
 
   VHCDR1 is GYTFTNYWIG  (SEQ ID NO:5)
 
   VHCDR2 is DIYPGGDYTNYNEKFKG  (SEQ ID NO:6)
 
   VHCDR3 is WGLGYYFDY  (SEQ ID NO:7)
 
 
       of an antibody produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301. 
     
     
       2. An antibody or fragment thereof as claimed in  claim 1  wherein the antibody is a monoclonal antibody. 
     
     
       3. An antibody or fragment thereof as claimed in  claim 2  wherein the monoclonal antibody is humanized. 
     
     
       4. An antibody or fragment thereof as claimed in  claim 1  wherein the fragment is a Fab, F(ab′) 2  or Fv fragment or an scFv molecule. 
     
     
       5. An antibody or fragment thereof as claimed in  claim 1  comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:19 and/or a light chain variable region having the amino acid sequence of SEQ ID NO:15. 
     
     
       6. An antibody or fragment thereof as claimed in  claim 1  produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301, wherein the antibody is a humanized monoclonal antibody. 
     
     
       7. A hybridoma cell line which produces an antibody or fragment thereof that binds the human Anx-A1 protein having the amino acid sequence of SEQ ID NO:8, said antibody or fragment thereof comprising wherein the antibody comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which
   VLCDR1 is KASENVVTYVS,  (SEQ ID NO:2)
 
   VLCDR2 is GASNRYT,  (SEQ ID NO:3)
 
   VLCDR3 is GQGYSYPYT,  (SEQ ID NO:4)
 
   VHCDR1 is GYTFTNYWIG,  (SEQ ID NO:5)
 
   VHCDR2 is DIYPGGDYTNYNEKFKG, and  (SEQ ID NO:6)
 
   VHCDR3 is WGLGYYFDY  (SEQ ID NO:7)
 
 
       of an antibody produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301. 
     
     
       8. A hybridoma cell line as claimed in  claim 7  deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301. 
     
     
       9. A pharmaceutical composition comprising an antibody or fragment thereof as claimed in  claim 1 . 
     
     
       10. A pharmaceutical composition as claimed in  claim 9 , further comprising another therapeutically active agent. 
     
     
       11. An antibody or fragment thereof as claimed in claim 1, wherein the antibody comprises:
 a light chain variable region produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301; and   a heavy chain variable region comprising Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which:   VHCDR1 is GYTFTNYWIG (SEQ ID NO:5),   VHCDR2 is DIYPGGDYTNYNEKFKG (SEQ ID NO:6), and   VHCDR3 is WGLGYYFDY (SEQ ID NO:7).   
     
     
       12. A humanized antibody comprising the fragment of the antibody as claimed in claim 11, wherein the fragment comprises the CDRs of the antibody defined in claim 11. 
     
     
       13. A hybridoma cell line as claimed in claim 7, wherein the antibody comprises:
 a light chain variable region produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301; and   a heavy chain variable region comprising Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which:   VHCDR1 is GYTFTNYWIG (SEQ ID NO:5),   VHCDR2 is DIYPGGDYTNYNEKFKG (SEQ ID NO:6), and   VHCDR3 is WGLGYYFDY (SEQ ID NO:7).